CD8A and lymphoma: CD8+ T cells from lymphoma patients show significantly higher surface CD107a expression when treated with the HSP90 inhibitor alone or in combinational treatment with HSP90 inhibitor and PD-1 inhibitors compared to healthy controls (Figure 3C).